Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 941-992-3 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
No specific studies are available on the absorption, distribution, metabolism, or excretion of the intermediate DCB 58%, but data on one of the main non-salified component 4,4'-sulfonyldiphenol (BPS), is available.
According to a 28-day repeated dose oral toxicity test on BPS in rats, 2 males died in the 1000 mg/kg bw/day group. In pathological examinations, changes were observed in the cecum, liver, thymus, adrenal, spleen, bone marrow and kidney.
Those findings suggest oral absorption and distribution to those organs in rats.
In general human populations, BPS (free plus conjugated) was found in 81% of 315 urine samples at concentrations ranging from below the LOQ (i. e.,0.02 ng/mL) to 21.0 ng/mL, with a mean value of 0.654 ng/mL (0.598μg/g Cre).1
The Dermal Permeability Coefficient Program (DERMWIN) v2.0 estimates the dermal permeability coefficient (Kp), the dermally absorbed dose per event (DAevent) and Dermal Absorbed Dose (DAD) of organic compounds via water contact.
The estimated Kp of BPS is 0.000767 cm/hr and the value suggests that the intermediate to be registered could be less absorbed by the skin.2
In a modelling study of 2010, dermal absorption was calculated to be 2.8% for sodium xylenesulphonate.3
Phenol, that is present in the whole mixture of the intermediate DCB in a low concentration (1.8%) is readily absorbed by the inhalation, oral, and dermal routes. Once absorbed, phenol is widely distributed in the body, although the levels in the lung, liver, and kidney are often reported as being higher than in other tissues (on a per-gram-tissue basis).
Elimination from the body is rapid, primarily as sulfate and glucuronide conjugates in the urine, regardless of the route of administration. Phenol does not appear to accumulate significantly in the body.4
The conclusion based on the available data is that DCB 58% could be orally absorbed, but much less absorbed through the skin.
References:
1SIDS INITIAL ASSESSMENT PROFILE, CoCAM 4, 16-18 April 2013;
2EPI Suite v. 4.11 (EPA’s office of Pollution Prevention Toxics and Syracuse Research Corporation SRC);
3ECHA Registration dossier, sodium xylenesulphonate CAS 1300 -72 -7;
4Toxicological review of phenol. EPA, IRIS, 2002, EPA/635/R-02/006.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
